Oxidative Stress as a Possible Target in the Treatment of Toxoplasmosis: Perspectives and Ambiguities.

Toxoplasma gondii is an apicomplexan parasite causing toxoplasmosis, a common disease, which is most typically asymptomatic. However, toxoplasmosis can be severe and even fatal in immunocompromised patients and fetuses. Available treatment options are limited, so there is a strong impetus to develop novel therapeutics. This review focuses on the role of oxidative stress in the pathophysiology and treatment of T. gondii infection. Chemical compounds that modify redox status can reduce the parasite viability and thus be potential anti-Toxoplasma drugs. On the other hand, oxidative stress caused by the activation of the inflammatory response may have some deleterious consequences in host cells. In this respect, the potential use of natural antioxidants is worth considering, including melatonin and some vitamins, as possible novel anti-Toxoplasma therapeutics. Results of in vitro and animal studies are promising. However, supplementation with some antioxidants was found to promote the increase in parasitemia, and the disease was then characterized by a milder course. Undoubtedly, research in this area may have a significant impact on the future prospects of toxoplasmosis therapy.

Ionizing Radiation as a Source of Oxidative Stress-The Protective Role of Melatonin and Vitamin D.

Ionizing radiation (IR) has found widespread application in modern medicine, including medical imaging and radiotherapy. As a result, both patients and healthcare professionals are exposed to various IR doses. To minimize the negative side effects of radiation associated with oxidative imbalance, antioxidant therapy has been considered. In this review, studies on the effects of melatonin and vitamin D on radiation-induced oxidative stress are discussed. According to the research data, both substances meet the conditions for use as agents that protect humans against IR-induced tissue damage. Numerous studies have confirmed that melatonin, a hydro- and lipophilic hormone with strong antioxidant properties, can potentially be used as a radioprotectant in humans. Less is known about the radioprotective effects of vitamin D, but the results to date have been promising. Deficiencies in melatonin and vitamin D are common in modern societies and may contribute to the severity of adverse side effects of medical IR exposure. Hence, supporting supplementation with both substances seems to be of first importance. Interestingly, both melatonin and vitamin D have been found to selectively radiosensitise cancer cells, which makes them promising adjuvants in radiotherapy. More research is needed in this area, especially in humans.

Melatonin supplementation improves oxidative and inflammatory state in the blood of professional athletes during the preparatory period for competitions.

Melatonin supplementation has been proved to have antioxidant and anti-inflammatory effects in humans. The aim of the study was to estimate the influence of a 30-day melatonin supplementation on oxidative and inflammatory state in the blood of intense training professional athletes. The study was conducted in 47 football players, 19 rowers, and 15 adults who did not practice sports (control group). Blood samples were taken once from the control group and twice from the athletes: before and after 30-day melatonin administration (5 mg daily before sleep). Serum levels of melatonin, isoprostanes, antiox-LDL antibodies, interleukin-6, and C-reactive protein were measured. In erythrocytes, the concentrations of reduced glutathione (GSH) and malondialdehyde (MDA), and the activities of glutathione peroxidase (GSH-Px), cytoplasmic superoxide dismutase (SOD-1), and glutathione reductase (GR) were determined. Melatonin supplementation caused a significant decrease in markers of oxidative stress and a significant increase in melatonin concentration and the activities of SOD-1 and GSH-Px in athletes. The obtained data showed increased oxidative stress and inflammatory processes in professional athletes during intense training and indicated that supplementation of melatonin in their daily diet may have a beneficial effect on the protection of tissues against the adverse action of RONS and inflammatory processes.

Melatonin Supplementation Lowers Oxidative Stress and Regulates Adipokines in Obese Patients on a Calorie-Restricted Diet.

Obesity is one of the major global health problems. Melatonin deficiency has been demonstrated to correlate with obesity. The aim of the study was to estimate the effect of melatonin on oxidative stress and adipokine levels in obese patients on a calorie-restricted diet. Thirty obese patients were supplemented with a daily dose of 10 mg of melatonin (n = 15) or placebo (n = 15) for 30 days with a calorie-restricted diet. Serum levels of melatonin, 4-hydroxynonenal (HNE), adiponectin, omentin-1, leptin, and resistin, as well as erythrocytic malondialdehyde (MDA) concentration and Zn/Cu-superoxide dismutase, catalase, and glutathione peroxidase (GPx) activities, were measured at baseline and after supplementation. Significant body weight reduction was observed only in the melatonin group. After melatonin supplementation, the adiponectin and omentin-1 levels and GPx activities statistically increased, whereas the MDA concentrations were reduced. In the placebo group, a significant rise in the HNE and a drop in the melatonin concentrations were found. The results show evidence of increased oxidative stress accompanying calorie restriction. Melatonin supplementation facilitated body weight reduction, improved the antioxidant defense, and regulated adipokine secretion. The findings strongly suggest that melatonin should be considered in obesity management. This trial is registered with CTRI/2017/07/009093.

Inter-relationships of the chronobiotic, melatonin, with leptin and adiponectin: implications for obesity.

Obesity and its medical complications represent a significant problem throughout the world. In recent decades, mechanisms underlying the progression of obesity have been intensively examined. The involvement of both the behavioral aspects, such as calorie-rich diet, low physical activity and sleep deprivation, and the intrinsic factors, including adipose tissue deregulation, chronic inflammation, oxidative stress, and chronodisruption, has been identified. The circadian disturbances of the adipose tissue endocrine function have been correlated with obesity. Leptin and adiponectin are adipokines strongly associated with glucose and lipid metabolism and with energy balance. Their synthesis and secretion display circadian rhythms that are disturbed in the obese state. Hyperleptinemia resulting in leptin resistance, and hypo-adiponectinemia have been linked to the pathophysiology of the obesity-related disorders. A deficiency of melatonin, one of the consequences of sleep deprivation, has also been demonstrated to correlate with obesity. Melatonin is a pineal secretory product involved in numerous actions, such as regulation of internal biological clocks and energy metabolism, and it functions as an antioxidant and as an anti-inflammatory agent. There exists a substantial amount of evidence supporting the beneficial effects of melatonin supplementation on obesity and its complications. In the current review, the results of studies related to the interactions between melatonin, and both leptin and adiponectin are discussed. Despite the existence of some inconsistencies, melatonin has been found to normalize the expression and secretion patterns of both adipokines. These results support the concept of melatonin as a potential therapeutic agent for obesity and related disorders.

Melatonin improves oxidative stress parameters measured in the blood of elderly type 2 diabetic patients.

An elevated oxidative status in the aging organism may be involved in the development of non-insulin dependent diabetes mellitus (NIDDM). Melatonin, a potent antioxidant agent, is essential for glucose homeostasis and regulation. The aim of this study was to determine the influence of melatonin supplementation on the oxidative stress parameters in elderly NIDDM patients. The malondialdehyde (MDA) concentration, Cu-Zn superoxide dismutase (SOD-1) activity in erythrocytes, the level of nitrate/nitrite in plasma and morning melatonin concentration and oxidase activity of ceruloplasmin (Cp) in serum in 15 elderly NIDDM patients at baseline and after the 30 days of melatonin supplementation (5 mg daily) in comparison with levels in 15 healthy elderly volunteers were determined. A significant increase of MDA level and decrease of SOD-1 activity and melatonin concentration were observed in NIDDM patients. Cp oxidase activity and nitrate/nitrite level were similar in both examined groups. Melatonin administration in NIDDM patients resulted in a significant increase in the morning melatonin concentration and SOD-1 activity, and a reduction in the MDA level and Cp oxidase activity. Statistically significant alterations in nitrate/nitrite levels were not observed. These results indicate an improvement of antioxidative defense after melatonin supplementation in the NIDDM individuals and suggest melatonin supplementation as an additional treatment for the control of diabetic complications.

[Time dependent effect of melatonin administration on lipid peroxidation, superoxide dismutase activity and melatonin concentration in the elderly patients with essential arterial hypertension]. / Wplyw melatoniny na procesy peroksydacji lipidów, aktywnosc dysmutazy ponadtlenkowej oraz stezenie melatoniny u osób w podeszlym wieku z pierwotnym nadcisnieniem tetniczym w zaleznosci od czasu suplementacji.

Oxidative stress and melatonin (the pineal hormone) are involved in the pathogenesis of aging and aging-related diseases, including essential arterial hypertension. The aim of study was determination of time dependent effect of melatonin administration on malondialdehyde (MDA) concentration, Cu, Zn-superoxide dismutase (SOD-1) activity and melatonin concentration in the elderly patients with essential arterial hypertension. The study was carried out on 11 patients with essential arterial hypertension (NT group, average 76.7 +/- 10 years), who were treated with thiazide diuretic. The reference group (K) was constituted 13 people without the chronic diseases (average 76.9 +/- 8 years). In the groups NT and K melatonin (Melatonin 5mg, LEKAM) one hour before sleep was administrated. MDA concentration and SOD-1 activity was performed before beginning of experiment and after 15 and after 30 days of the melatonin administration. Melatonin concentration was determined before beginning of experiment and after 30 days of the melatonin administration. Venous blood was taken from the cubital vein at 08.00 am. Melatonin concentration was determined in serum, and MDA content and SOD-1 acitivity were determined in erythrocytes. In NT group in comparison to K group non-significant higher MDA concentration (0.293 +/- 0.03 and 0.286 +/- 0.03 micromol/g Hb, respectively), lower SOD-1 activity (2591 +/- 304.1 and 2630 +/- 301 U/g Hb, respectively) and lower melatonin concentration (7.65 +/- 4.6 and 8.36 +/- 4.7 pg/ml, respectively) were observed. After 15 days of melatonin administration lower MDA concentration and higher SOD-1 activity: in NT group (0.250 +/- 0.03, p < 0.01 and 2757 +/- 299, NS, respectively) and in K group (0.264 +/- 0.03, NS and 3065 +/- 529, p < 0.02, respectively) were measured. After 30 days of supplementation MDA concentration further decreased in NT group (0.247 +/- 0.03, NS) and in K group (0.240 +/- 0.03, p < 0.002). However, after 30 days of melatonin administration in comparison to the results of 15 days the statistically non-significant differences of SOD-1 activity, either in NT group (2680 +/- 332 U/g Hb) and in K group (3012 +/- 417 U/g Hb) were observed. After 30 days of supplementation melatonin concentration increased in NT group (19.57 +/- 11.7 pg/ml, p < 0.01) and in K group (19.33 +/- 17.8 pg/ml, p < 0.05). The results may indicate on the intensification of oxidative stress in elderly patients with essential arterial hypertension and on the beneficial antioxidant effect of melatonin, already after 15 days of supplementation. This results may have indicates on the therapeutic implications.

Antioxidative effects of melatonin administration in elderly primary essential hypertension patients.

The imbalance of the redox state of the aging organism may be involved in the development of primary essential hypertension. Melatonin, a potent antioxidant agent, was found to exert a hypotensive effect and improve the function of the cardiovascular system. The aim of this study was to determine the influence of melatonin supplementation on oxidative stress parameters in elderly primary essential hypertensive (EH) patients, controlled by a diuretic (indapamide) monotherapy. The levels of malondialdehyde (MDA) and reduced glutathione (GSH), activities of Cu-Zn superoxide dismutase (SOD-1), catalase (CAT) and glutathione peroxidase (GSH-Px) in erythrocytes, the plasma level of nitrate/nitrite, the content of carbonyl groups of plasma proteins and morning melatonin levels in the serum of 17 elderly EH patients were determined at the baseline and after the 15th and 30th days of melatonin supplementation (5 mg daily). Melatonin administration resulted in a significant increase in the morning melatonin concentration, SOD-1 and CAT activities, and a reduction in the MDA level. Statistically significant alterations in the levels of GSH, nitrate/nitrite and carbonyl groups and the activity of GSH-Px were not observed. These results indicate an improvement in the antioxidative defense of the organism by melatonin supplementation in the examined group and may suggest melatonin supplementation as an additional treatment supporting hypotensive therapy in elderly EH patients.

Effect of melatonin on the oxidative stress in erythrocytes of healthy young and elderly subjects.

The disturbances in pro- and antioxidant balance may play an important role in the pathomechanism of aging. The pineal hormone melatonin, which exerts effective antioxidative properties, is suggested to be involved in the aging process. The aim of this study was to compare the oxidative stress in erythrocytes of healthy young adults and elderly people, and to determine the influence of melatonin supplementation on measured parameters in both examined groups. The malondialdehyde (MDA) and reduced glutathione levels as well as Cu-Zn superoxide dismutase (SOD-1), catalase, glutathione peroxidase (GSH-Px), glutathione S-transferase (GST) and glutathione reductase (GR) activities in erythrocytes and morning serum melatonin concentration in 14 healthy young adults and 14 healthy elderly people at baseline and after the 30th day of melatonin (5 mg daily) supplementation were determined. A significant age effect on increasing the MDA level and decreasing SOD-1, GSH-Px and GR activities as well as melatonin concentration was observed. Melatonin supplementation resulted in a significant increase in melatonin concentration, SOD-1 and GR activities and a decrease in the MDA level in both examined groups. These data indicate an age-related augmentation of oxidative stress in erythrocytes and the improvement of erythrocytic antioxidative defense by melatonin administration. These results might suggest melatonin supplementation to prevent age-related diseases and to prolong the lifespan and improve the quality of life of elderly people.

Selenium level in benign and cancerous prostate.

The dietary microelement selenium (Se) has been proposed as a potential chemopreventive agent for prostate cancer. This element is present in various amounts in all tissues. Little information is available on Se level in patients with prostate gland disorders. The levels of Se in prostatic gland of patients with prostate cancer, benign prostate hyperplasia, and healthy controls were examined. The Se level for benign prostate hyperplasia (156 +/- 30.6 ng/g) was the same as in the control group (157 +/- 26.0 ng/g), but in the gland of prostate cancer patients (182 +/- 34.1 ng/g wet weight), the Se level was significantly (p < 0.01) higher than in both healthy controls and benign prostate hyperplasia. Thus, the Se level in human healthy controls is lower than in kidney and liver but higher compared with other tissues.